Metformin for type 2 diabetes patients or not? Researchers now have the answer

September 17, 2020

Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients. One third of patients do not respond to metformin treatment and 5 per cent experience serious side effects, which is the reason many choose to stop medicating. Researchers at Lund University in Sweden have now identified biomarkers that can show in advance how the patient will respond to metformin treatment via a simple blood test.

"Our study constitutes an important step towards the goal of personalised care for diabetes patients because it can contribute to ensuring that the right person receives the right care as soon as there is a diagnosis", says Charlotte Ling, professor of epigenetics at Lund University, who led the study.

When diet and exercise are not enough to regulate blood sugar, metformin is the first drug introduced to treat type 2 diabetes, according to international guidelines. If it does not have the intended effect in the form of lowered blood sugar levels, or if the patient experiences serious side effects, patients then go on to trial other drugs.

"If it takes a long time for the patient to receive the correct treatment, there is a risk of complications due to the elevated blood sugar levels. Approximately 30 per cent of all patients with type 2 diabetes do not respond to metformin and should be given another drug right from the start. For this reason, it is important to be able to identify these patients upon diagnosis", says Charlotte Ling.

One third of patients experience side effects usually in the form of gastrointestinal difficulties such as nausea, stomach pain and diarrhoea. Five per cent stop taking the medicine due to severe side effects.

The study is the first pharmacoepigenetic study in diabetes, i.e. that researchers have studied how epigenetic factors, such as DNA methylation (see fact box), can be used as biomarkers to predict the effect of a drug.

"To a certain extent, pharmacoepigenetics has been used within cancer care to predict how a person will respond to a treatment, however, it has never been done in diabetes care before", says Charlotte Ling.

Researchers in the study have looked at epigenetic modifications, so-called DNA methylations, in blood from individuals diagnosed with diabetes before they started taking metformin. In a follow-up a year later, the researchers could see which patients had benefited from the treatment (with resulting lowered blood sugar levels) and whether or not they had suffered from side effects.

"By compiling the responses, we have found biomarkers that can identify already at diagnosis of diabetes which patients will benefit from and tolerate metformin, which will advance personalised therapy in type 2 diabetes", says the study's first author Sonia García-Calzón.

The study was conducted on 363 participants from three different patient cohorts (All New Diabetics in Skåne, All New Diabetics in Uppsala and Optimed from Latvia). As a next step, the researchers are planning for a new clinical study in which they will repeat the study with a larger patient group - 1000 patients will be invited to participate from all around the world.
-end-


Lund University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.